Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Is Paradoxical Pain Induced by Sustained Opioid Exposure an Underlying Mechanism of Opioid Antinociceptive Tolerance?

King T. · Ossipov M.H. · Vanderah T.W. · Porreca F. · Lai J.

Author affiliations

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Ariz., USA

Corresponding Author

Josephine Lai, PhD

Department of Pharmacology, University of Arizona Health Sciences Center

1501 N. Campbell Ave.

Tucson, AZ 85724 (USA)

Tel. +1 520 626 2147, Fax +1 520 626 4182, E-Mail lai@u.arizona.edu

Related Articles for ""

Neurosignals 2005;14:194–205

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Opiates are the primary treatment for pain management in cancer patients reporting moderate to severe pain, and are being increasingly used for non-cancer chronic pain. However, prolonged administration of opiates is associated with significant problems including the development of antinociceptive tolerance, wherein higher doses of the drug are required over time to elicit the same amount of analgesia. High doses of opiates result in serious side effects such as constipation, nausea, vomiting, dizziness, somnolence, and impairment of mental alertness. In addition, sustained exposure to morphine has been shown to result in paradoxical pain in regions unaffected by the initial pain complaint, and which may also result in dose escalation, i.e. ‘analgesic tolerance’. A concept that has been gaining considerable experimental validation is that prolonged use of opioids elicits paradoxical, abnormal pain. This enhanced pain state requires additional opioids to maintain a constant level of antinociception, and consequently may be interpreted as antinociceptive tolerance. Many substances have been shown to block or reverse antinociceptive tolerance. A non-inclusive list of examples of substances reported to block or reverse opioid antinociceptive tolerance include: substance P receptor (NK-1) antagonists, calcitonin gene-related peptide (CGRP) receptor antagonists, nitric oxide (NO) synthase inhibitors, calcium channel blockers, cyclooxygenase (COX) inhibitors, protein kinase C inhibitors, competitive and non-competitive antagonists of the NMDA (N-methyl-D-aspartate) receptor, AMPA (alpha-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid) antagonists, anti-dynorphin antiserum, and cholecystokinin (CCK) receptor antagonists. Without exception, these substances are also antagonists of pain-enhancing agents. Prolonged opiate administration indeed induces upregulation of substance P (SP) and calcitonin gene-related peptide (CGRP) within sensory fibers in vivo, and this is accompanied by an enhanced release of excitatory neurotransmitters and neuropeptides from primary afferent fibers upon stimulation. The enhanced evoked release of neuropeptides is correlated with the onset of abnormal pain states and opioid antinociceptive tolerance. Importantly, the descending pain modulatory pathway from the brainstem rostral ventromedial medulla (RVM) via the dorsolateral funiculus (DLF) is critical for maintaining the changes observed in the spinal cord, abnormal pain states and antinociceptive tolerance, because animals with lesion of the DLF did not show enhanced evoked neuropeptide release, or develop abnormal pain or antinociceptive tolerance upon sustained exposure to opiates. Microinjection of either lidocaine or a CCK antagonist into the RVM blocked both thermal and touch hypersensitivity as well as antinociceptive tolerance. Thus, prolonged opioid exposure enhances a descending pain facilitatory pathway from the RVM that is mediated at least in part by CCK activity and is essential for the maintenance of antinociceptive tolerance.

© 2005 S. Karger AG, Basel


  1. Kalso E, et al: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372–380.
  2. Blum RH, et al: The multidisciplinary approach to bone metastases. Oncology (Huntingt) 2003;17:845–857; discussion 862–863, 867.
  3. Cox BM: Drug tolerance and physical dependence; in Wall PD, Taylor P (eds): Principles of Drug Action: The Basis of Pharmacology. New York, Churchill-Livingstone, 1990, pp 639–690.
  4. Foley KM: Opioids. Neurol Clin 1993;11:503–522.
  5. Foley KM: Misconceptions and controversies regarding the use of opioids in cancer pain. Anti-Cancer Drugs 1995;6(suppl 3):4–13.
  6. Way EL, Loh HH, Shen FH: Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 1969;167:1–8.
  7. Cherney NI, Portenoy RK: Practical issues in the management of cancer pain; in Wall PD, Melzack R (eds): Textbook of Pain. Edinburgh, Churchill-Livingstone, 1999, pp 1479–1522.
  8. Fernandes M, Kluwe S, Coper H: The development of tolerance to morphine in the rat. Psychopharmacology (Berl) 1977;54:197–201.
  9. Fernandes M, Kluwe S, Coper H: Quantitative assessment of tolerance to and dependence on morphine in mice. Naunyn Schmiedebergs Arch Pharmacol 1977;297:53–60.
  10. Yaksh TL, Kohl RL, Rudy TA: Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarachnoid space. Eur J Pharmacol 1977;42:275–284.
  11. Roerig SC, Fujimoto JM: Morphine antinociception in different strains of mice: relationship of supraspinal-spinal multiplicative interaction to tolerance. J Pharmacol Exp Ther 1988;247:603–608.
  12. Roerig SC, et al: Tolerance to morphine analgesia: decreased multiplicative interaction between spinal and supraspinal sites. Brain Res 1984;308:360–363.
  13. Vanderah TW, et al: Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000;20:7074–7079.
  14. Quock RM, et al: The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev 1999;51:503–532.
  15. Connor M, Christie MJ: Opioid receptor signaling mechanisms. Clin Exp Pharmacol Physiol 1999;26:493–499.
  16. Williams JT, Christie MJ, Manzoni O: Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001;81:299–343.
  17. Ostermeier AM, et al: Activation of mu- and delta-opioid receptors causes presynaptic inhibition of glutamatergic excitation in neocortical neurons. Anesthesiology 2000;93:1053–1063.
  18. Yaksh TL, et al: Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature 1980;286:155–157.
  19. Xin L, et al: Substance P release in the rat periaqueductal gray and preoptic anterior hypothalamus after noxious cold stimulation: effect of selective mu and kappa opioid agonists. J Pharmacol Exp Ther 1997;282:1055–1063.
  20. Gamse R, Holzer P, Lembeck F: Indirect evidence for presynaptic location of opiate receptors on chemosensitive primary sensory neurones. Naunyn Schmiedebergs Arch Pharmacol 1979;308:281–285.
  21. Abbadie C, et al: Mu and delta opioid receptor-like immunoreactivity in the cervical spinal cord of the rat after dorsal rhizotomy or neonatal capsaicin: an analysis of pre- and postsynaptic receptor distributions. Brain Res 2002;930:150–162.
  22. Lamotte C, Pert CB, Snyder SH: Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section. Brain Res 1976;112:407–412.
  23. Chavkin C, Goldstein A: Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea. Life Sci 1982;31:1687–1690.
  24. von Zastrow M: Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. Life Sci 2003;74:217–224.
  25. Ferguson SS: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53:1–24.
  26. Ferguson SS, et al: Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. Adv Pharmacol 1998;42:420–424.
  27. Ferguson SS, et al: Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci 1998;62:1561–1565.
  28. Goodman CB, et al: Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptides. Peptides 1998;19:1703–1709.
  29. Terman GW, et al: G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 2004;141:55–64.
  30. Chu P, et al: Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. J Biol Chem 1997;272:27124–27130.
  31. Lefkowitz RJ: G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998;273:18677–18680.
  32. Lefkowitz RJ, et al: Mechanisms of beta-adrenergic receptor desensitization and resensitization. Adv Pharmacol 1998;42:416–420.
  33. Przewlocka B, et al: Knockdown of spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance and allodynia in rat. Neurosci Lett 2002;325:107–110.
  34. Bohn LM, et al: Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000;408:720–723.
  35. Bohn LM, Lefkowitz RJ, Caron MG: Differential mechanisms of morphine antinociceptive tolerance revealed in beta arrestin-2 knock-out mice. J Neurosci 2002;22:10494–10500.
  36. Bohn LM, et al: Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 2004;66:106–112.
  37. Bohn LM, et al: Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999;286:2495–2458.
  38. Arden JR, et al: Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 1995;65:1636–1645.
  39. Alvarez VA, et al: mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 2002;22:5769–5776.
  40. von Zastrow M, et al: Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs. Curr Opin Neurobiol 2003;13:348–353.
  41. Keith DE, et al: Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996;271:19021–19024.
  42. Whistler JL, et al: Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 1999;23:737–746.
  43. Zhang J, et al: Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 1998;95:7157–7162.
  44. Whistler JL, von Zastrow M: Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998;95:9914–9919.
  45. Keith DE, et al: mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998;53:377–384.
  46. Sternini C, et al: Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 1996;93:9241–9246.
  47. He L, et al: Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002;108:271–282.
  48. Finn AK, Whistler JL: Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001;32: 829–839.
  49. Stevens CW, Yaksh TL: Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther 1989;250:1–8.
  50. Rezvani A, et al: A rapid and simple method for the quantitative determination of tolerance development to opiates in the guinea-pig ileum in vitro. J Pharmacol Exp Ther 1983;225:251–255.
  51. Duttaroy A, Yoburn BC: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995;82:1226–1236.
  52. Nestler EJ: Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 1993;7:23–39.
  53. Varga EV, et al: Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sci 2003;74:299–311.
  54. Rubenzik M, et al: Expression of alpha-transducin in Chinese hamster ovary cells stably transfected with the human delta-opioid receptor attenuates chronic opioid agonist-induced adenylyl cyclase superactivation. Mol Pharmacol 2001;60:1076–1082.
  55. Avidor-Reiss T, et al: Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem 1995;270:29732–29738.
  56. Ammer H, Christ TE: Identity of adenylyl cyclase isoform determines the G protein mediating chronic opioid-induced adenylyl cyclase supersensitivity. J Neurochem 2002;83:818–827.
  57. Ammer H, Schulz R: Adenylyl cyclase supersensitivity in opioid-withdrawn NG108-15 hybrid cells requires Gs but is not mediated by the Gsalpha subunit. J Pharmacol Exp Ther 1998;286:855–862.
  58. Chakrabarti S, et al: Chronic morphine augments adenylyl cyclase phosphorylation: relevance to altered signaling during tolerance/dependence. Mol Pharmacol 1998;54:949–953.
  59. Chakrabarti S, et al: Chronic morphine augments G(beta)(gamma)/Gs(alpha) stimulation of adenylyl cyclase: relevance to opioid tolerance. Mol Pharmacol 1998;54:655–662.
  60. Alves ID, et al: Selectivity, cooperativity, and reciprocity in the interactions between the {delta}-opioid receptor, its ligands, and G-proteins. J Biol Chem 2004;279:44673–44682.
  61. Crain SM, Shen K-F: Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000;84:121–131.
  62. Sunahara RK, Dessauer CW, Gilman AG: Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 1996;36:461–480.
  63. Taussig R, Gilman AG: Mammalian membrane-bound adenylyl cyclases. J Biol Chem 1995;270:1–4.
  64. Varga EV, et al: Phosphorylation of adenylyl cyclase VI upon chronic delta-opioid receptor stimulation. Eur J Pharmacol 1999;364:R1–R3.
  65. Tan CM, et al: Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry 2001;40:1702–1709.
  66. Varga EV, et al: Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic {delta}-opioid agonist treatment. J Pharmacol Exp Ther 2003;306:109–115.
  67. Chuang LF, Killam KF Jr, Chuang RY: Induction and activation of mitogen-activated protein kinases of human lymphocytes as one of the signaling pathways of the immunomodulatory effects of morphine sulfate. J Biol Chem 1997;272:26815–26817.
  68. Li LY, Chang KJ: The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors. Mol Pharmacol 1996;50:599–602.
  69. Li X, Clark JD: Morphine tolerance and transcription factor expression in mouse spinal cord tissue. Neurosci Lett 1999;272:79–82.
  70. Ma W, et al: Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. Eur J Neurosci 2001;14:1091–1104.
  71. Guitart X, et al: Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem 1992;58:1168–1171.
  72. Bilecki W, Hollt V, Przewlocki R: Acute delta-opioid receptor activation induces CREB phosphorylation in NG108-15 cells. Eur J Pharmacol 2000;390:1–6.
  73. Powell KJ, Quirion R, Jhamandas K: Inhibition of neurokinin-1-substance&nbsp. P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur J Neurosci 2003;18:1572–1583.
  74. Caivano M, Cohen P: Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 2000;164:3018–3025.
  75. Davis S, et al: The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 2000;20:4563–4572.
  76. Freeland K, Liu YZ, Latchman DS: Distinct signalling pathways mediate the cAMP response element (CRE)-dependent activation of the calcitonin gene-related peptide gene promoter by cAMP and nerve growth factor. Biochem J 2000;345:233–238.
  77. Watson A, et al: A minimal CGRP gene promoter is inducible by nerve growth factor in adult rat dorsal root ganglion neurons but not in PC12 phaeochromocytoma cells. Eur J Neurosci 1995;7:394–400.
  78. Watson A, Latchman D: The cyclic AMP response element in the calcitonin/calcitonin gene-related peptide gene promoter is necessary but not sufficient for its activation by nerve growth factor. J Biol Chem 1995;270:9655–9660.
  79. Qian J, et al: Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5′-monophosphate response elements in its expression by IL-1 and stem cell factor. J Immunol 2001;166:2553–2561.
  80. Jhamandas K, et al: Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J Neurosci 1996;16:2758–2766.
  81. Gardell LR, et al: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002;22:6747–6755.
  82. Trang T, et al: The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol 2002;136:37–48.
  83. Ossipov MH, et al: Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci 2003;73:783–800.
  84. Yaksh TL, Harty GJ: Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988;244:501–507.
  85. Mao J, Price DD, Mayer DJ: Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:259–274.
  86. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251:85–87.
  87. Laulin JP, et al: Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 1999;89:631–636.
  88. Colpaert FC: System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev 1996;48:355–402.
  89. Gutstein HB: The effects of pain on opioid tolerance: how do we resolve the controversy? Pharmacol Rev 1996;48:403–407; discussion 409–411.
  90. Vanderah TW, et al: Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 2001;92:5–9.
  91. Vanderah TW, et al: Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001;21:279–286.
  92. Bian D, et al: Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Res 1999;831:55–63.
  93. Mao J, Price DD, Mayer DJ: Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995;61:353–364.
  94. Wegert S, et al: Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats. Pain 1997;71:57–64.
  95. Baranauskas G, Nistri A: Sensitization of pain pathways in the spinal cord: cellular mechanisms. Prog Neurobiol 1998;54:349–365.
  96. Haley JE, Wilcox GL, Chapman PF: The role of nitric oxide in hippocampal long-term potentiation. Neuron 1992;8:211–216.
  97. Larcher A, et al: Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience 1998;84:583–589.
  98. Celerier E, et al: Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000;92:465–472.
  99. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301–2312.
  100. Tiseo PJ, et al: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J Pharmacol Exp Ther 1994;268:195–201.
  101. Tiseo PJ, Inturrisi CE: Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 1993;264:1090–1096.
  102. Manning BH, et al: Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain 1996;67:79–88.
  103. Celerier E, et al: Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res 1999;847:18–25.
  104. Laulin JP, et al: Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci 1998;10:782–785.
  105. Celerier E, et al: Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001;21:4074–4080.
  106. Liu H, et al: Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the spinal cord dorsal horn. Proc Natl Acad Sci USA 1994;91:8383–8387.
  107. Liu H, Mantyh PW, Basbaum AI: NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997;386:721–724.
  108. Akil H, et al: Endogenous opioids: biology and function. Annu Rev Neurosci 1984;7:223–255.
  109. Ossipov MH, et al: Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat. Neurosci Lett 1994;181:9–12.
  110. Goldstein A, et al: Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979;76:6666–6670.
  111. Dubner R, Ruda MA: Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992;15:96–103.
  112. Draisci G, et al: Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res 1991;560:186–192.
  113. Kajander KC, et al: Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 1990;11:719–728.
  114. Wagner R, Deleo JA: Pre-emptive dynorphin and N-methyl-D-aspartate glutamate receptor antagonism alters spinal immunocytochemistry but not allodynia following complete peripheral nerve injury. Neuroscience 1996;72:527–534.
  115. Wagner R, et al: Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model. Brain Res 1993;629:323–326.
  116. Malan TP, et al: Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 2000;86:185–194.
  117. Wang Z, et al: Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 2001;21:1779–1786.
  118. Pohl M, et al: Enkephalinergic and dynorphinergic neurons in the spinal cord and dorsal root ganglia of the polyarthritic rat – in vivo release and cDNA hybridization studies. Brain Res 1997;749:18–28.
  119. Laughlin TM, et al: Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997;72:253–260.
  120. Vanderah TW, et al: Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 1996;68:275–281.
  121. Gardell LR, et al: Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance. Pain 2002;98:79–88.
  122. Skilling SR, et al: Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity. Brain Res 1992;575:272–278.
  123. Koetzner L, et al: Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2. J. Neurosci 2004;24:1451–1458.
  124. Faden AI: Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J Neurosci 1992;12:425–429.
  125. Arcaya JL, et al: Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. Eur J Pharmacol 1999;366:27–34.
  126. Fields HL, Heinricher MM: Anatomy and physiology of a nociceptive modulatory system. Philos Trans R Soc Lond [B] 1985;308:361–374.
  127. Fields HL, et al: The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. J Neurosci 1983;3:2545–2552.
  128. Fields HL, et al: Evidence that disinhibition of brain stem neurones contributes to morphine analgesia. Nature 1983;306:684–686.
  129. Calejesan AA, Kim SJ, Zhuo M: Descending facilitatory modulation of a behavioral nociceptive response by stimulation in the adult rat anterior cingulate cortex. Eur J Pain 2000;4:83–96.
  130. Zhuo M, Gebhart GF: Biphasic modulation of spinal nociceptive transmission from the medullary raphe nuclei in the rat. J Neurophysiol 1997;78:746–758.
  131. Zhuo M, Gebhart GF: Characterization of descending facilitation and inhibition of spinal nociceptive transmission from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. J Neurophysiol 1992;67:1599–1614.
  132. Urban MO, Gebhart GF: Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci USA 1999;96:7687–7692.
  133. Urban MO, Gebhart GF: Central mechanisms in pain. Med Clin N Am 1999;83:585–596.
  134. McNally GP: Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance. Neurosci Biobehav Rev 1999;23:1059–1078.
  135. Kaplan H, Fields HL: Hyperalgesia during acute opioid abstinence: evidence for a nociceptive facilitating function of the rostral ventromedial medulla. J Neurosci 1991;11:1433–1439.
  136. Heinricher MM, Roychowdhury SM: Reflex-related activation of putative pain facilitating neurons in rostral ventromedial medulla requires excitatory amino acid transmission. Neuroscience 1997;78:1159–1165.
  137. Zhuo M, Gebhart GF: Characterization of descending inhibition and facilitation from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. Pain 1990;42:337–350.
  138. Urban MO, Gebhart GF: Characterization of biphasic modulation of spinal nociceptive transmission by neurotensin in the rat rostral ventromedial medulla. J Neurophysiol 1997;78:1550–1562.
  139. Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends Neurosci 2002;25:319–325.
  140. Heinricher MM, Morgan MM, Fields HL: Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience 1992;48:533–543.
  141. Kim DH, Fields HL, Barbaro NM: Morphine analgesia and acute physical dependence: rapid onset of two opposing, dose-related processes. Brain Res 1990;516:37–40.
  142. Bederson JB, Fields HL, Barbaro NM: Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens Mot Res 1990;7:185–203.
  143. Morgan MM, Fields HL: Pronounced changes in the activity of nociceptive modulatory neurons in the rostral ventromedial medulla in response to prolonged thermal noxious stimuli. J Neurophysiol 1994;72:1161–1170.
  144. Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, Porreca F: Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 2002;22:5129–5136.
  145. Baber NS, Dourish CT, Hill DR: The role of CCK caerulein, and CCK antagonists in nociception. Pain 1989;39:307–328.
  146. Savasta M, Palacios JM, Mengod G: Regional localization of the mRNA coding for the neuropeptide cholecystokinin in the rat brain studied by in situ hybridization. Neurosci Lett 1988;93:132–138.
  147. Stengaard-Pedersen K, Larsson LI: Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system. Peptides 1981;2(suppl 1):3–19.
  148. Ghilardi JR, et al: Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 1992;12:4854–4866.
  149. Hokfelt T, et al: Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons. J Chem Neuroanat 1988;1:11–51.
  150. Skinner K, Basbaum AI, Fields HL: Cholecystokinin and enkephalin in brain stem pain modulating circuits. Neuroreport 1997;8:2995–2998.
  151. Mantyh PW, Hunt SP: Evidence for cholecystokinin-like immunoreactive neurons in the rat medulla oblongata which project to the spinal cord. Brain Res 1984;291:49–54.
  152. Verge VM, Wiesenfeld-Hallin Z, Hokfelt T: Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies in rat and monkey. Eur J Neurosci 1993;5:240–250.
  153. Stanfa LC, Dickenson AH: Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br J Pharmacol 1993;108:967–973.
  154. Hong EK, Takemori AE: Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. J Pharmacol Exp Ther 1989;251:594–598.
  155. Jeftinija S, Miletic V, Randic M: Cholecystokinin octapeptide excites dorsal horn neurons both in vivo and in vitro. Brain Res 1981;213:231–236.
  156. Pittaway KM, et al: CCK 8 analgesia and hyperalgesia after intrathecal administration in the rat: comparison with CCK-related peptides. Neuropeptides 1987;10:87–108.
  157. Faris PL: Opiate antagonistic function of cholecystokinin in analgesia and energy balance systems. Ann NY Acad Sci 1985;448:437–447.
  158. Hughes J, Hunter JC, Woodruff GN: Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Neuropeptides 1991;19(suppl):85–89.
  159. Suh HH, Tseng LF: Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice. Eur J Pharmacol 1990;179:329–338.
  160. Watkins LR, et al: Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res 1985;327:181–190.
  161. Watkins LR, Kinscheck IB, Mayer DJ: Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 1985;327:169–180.
  162. Dourish CT, Hawley D, Iversen SD: Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur J Pharmacol 1988;147:469–472.
  163. Vanderah TW, et al: Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors. J Pharmacol Exp Ther 1996;278:212–219.
  164. Vanderah TW, et al: Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole- and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception. Neuroreport 1994;5:2601–2605.
  165. Maldonado R, et al: Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 1993;4:947–950.
  166. Noble F, Derrien M, Roques BP: Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 1993;109:1064–1070.
  167. Wiesenfeld-Hallin Z, Xu X-J: The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Regul Pept 1996;65:23–28.
  168. Heinricher MM, McGaraughty S, Tortorici V: Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001;85:280–286.
  169. Kovelowski CJ, et al: Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain 2000;87:265–273.
  170. Xie JY, et al: Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 2005;25:409–416.
  171. Zhou Y, et al: Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. Neuroreport 1992;3:1121–1123.
  172. Zhou Y, et al: Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 1993;234:147–154.
  173. Stanfa L, et al: Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 1994;15:65–66.
  174. de Araujo Lucas G, et al: Differential release of cholecystokinin by morphine in rat spinal cord. Neurosci Lett 1998;245:13–16.
  175. Becker C, et al: Delta(2)-opioid receptor mediation of morphine-induced CCK release in the frontal cortex of the freely moving rat. Synapse 1999;34:47–54.
  176. Ding XZ, Bayer BM: Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res 1993;625:139–144.
  177. Pu S, et al: Cholecystokinin gene expression in rat amygdaloid neurons: normal distribution and effect of morphine tolerance. Brain Res Mol Brain Res 1994;21:183–189.
  178. Pu SF, Zhuang HX, Han JS: Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor. Brain Res 1994;657:159–164.
  179. Lucas GA, et al: Extracellular cholecystokinin levels in the rat spinal cord following chronic morphine exposure: an in vivo microdialysis study. Brain Res 1999;821:79–86.
  180. Kellstein DE, Mayer DJ: Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance. Pain 1991;47:221–229.
  181. Xu XJ, et al: CI988, a selective antagonist of cholecystokinin B receptors, prevents morphine tolerance in the rat. Br J Pharmacol 1992;105:591–596.
  182. Ding XZ, et al: Reversal of tolerance to morphine but no potentiation of morphine-induced analgesia by antiserum against cholecystokinin octapeptide. Neuropharmacology 1986;25:1155–1160.
  183. Hoffmann O, Wiesenfeld-Hallin Z: The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats. Neuroreport 1994;5:2565–2568.
  184. Singh L, et al: Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. Br J Pharmacol 1996;118:1317–1325.
  185. Heinricher MM, Neubert MJ: Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004;1009:223–227.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: October 13, 2005
Issue release date: October 2005

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISSN: 1424-862X (Print)
eISSN: 1424-8638 (Online)

For additional information: https://www.karger.com/NSG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.